Search Medical Condition
Please enter condition
Please choose location from dropdown

Chuo-ku Sapporo, Japan Clinical Trials

A listing of Chuo-ku Sapporo, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (132) clinical trials

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).

Phase

0.38 miles

Learn More »

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

Phase

0.38 miles

Learn More »

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_

The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy ...

Phase

0.38 miles

Learn More »

Japanese Idiopathic Interstitial Pneumonias Registry

JIPS Registry is a multi-site, non-interventional, prospective observation study of patients with newly diagnosed IIPs in Japan. At least 600 patients will be registered for 16 months at approximately 80 sites in Japan. Primary research question is to determine the natural history of each category of IIPs at registration, patient ...

Phase N/A

0.38 miles

Learn More »

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Phase

0.38 miles

Learn More »

Heart Failure and Sudden Cardiac Death Japan Registry

The purpose of this observational registry is to collect clinical events and outcome data in 4 different study populations (cohorts), with a majority of Japanese subjects, that are at risk of sudden cardiac death (SCD) and heart failure (HF) events. These event rates will be compared with available published data ...

Phase N/A

0.38 miles

Learn More »

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

Phase

0.38 miles

Learn More »

A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

The study consists of 3 sub-studies, as follows: Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in subjects with moderately to severely active Crohn's disease (CD) who responded to risankizumab induction treatment in Study M16-006 or Study M15-991 ...

Phase

0.38 miles

Learn More »

A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to ...

Phase

0.38 miles

Learn More »

Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?

Recently, the investigators found that a significant proportion of subjects in a general population shows attenuated secretion of active GLP-1 in response to oral glucose loading and that the insufficient secretion of GLP-1 was independently associated with elevation of blood pressure (BP) (Yoshihara et al. PLoS One 2013;8:e67578). In that ...

Phase N/A

0.45 miles

Learn More »